Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14262594 | 0.85 | AHCY (0.45) | IDUAAHCYHSP90AA1ADORA3HSP90B1 | |
| SCHEMBL29302102 | 0.84 | HOGA1 (0.34) | EPHX2HSP90AA1ADORA3HSP90B1ADORA2A | |
| SCHEMBL29300514 | 0.75 | FOLH1 (0.35) | EPHX2CA1CA2CA9 | |
| SCHEMBL29299846 | 0.73 | ADORA3 (0.33) | ADORA3 | |
| SCHEMBL13703576 | 0.71 | MEN1 (0.35) | EPHX2 | |
| SCHEMBL19502461 | 0.69 | HOGA1 (0.30) | IDUACA1CA2CA9 | |
| SCHEMBL8331534 | 0.68 | PYGB (0.44) | EPHX2CA1CA2CA9 | |
| SCHEMBL18819632 | 0.66 | IDUA (0.72) | IDUACA1CA2CA9 | |
| SCHEMBL19784469 | 0.66 | IDUA (0.72) | IDUACA1CA2CA9 | |
| SCHEMBL18819649 | 0.66 | IDUA (0.72) | IDUACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | IDUA 2929/4885EPHX2 3074/4885AHCY 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.